Reset
Showing 1 of 1 academic articles

A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation

Liya Ma, Bin Liang, Huixian Hu, Wenli Yang et al. • Frontiers in Oncology (2022)

The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS...

DOAJ Open Access (DOAJ) DOI: 10.3389/fonc.2022.905490